Patents Assigned to Myriad Genetics, Inc.
  • Hereditary cancer genes
    Patent number: 11104956
    Abstract: The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 31, 2021
    Assignee: Myriad Genetics, Inc.
    Inventors: Kirsten Timms, Brian Allen, Anne-Renee Hartman
  • METHODS AND SYSTEMS FOR SOMATIC MUTATIONS AND USES THEREOF
    Publication number: 20210262016
    Abstract: This invention provides methods and compositions for detecting somatic mutations in cancer cells. The methods can be used for measuring tumor mutation burden. Provided are methods for identifying and treating subjects who benefit from treatment with anticancer agents such as immune checkpoint inhibitors, methods for treating cancer in a subject, and methods for monitoring and prognosing a subject having cancer.
    Type: Application
    Filed: May 6, 2021
    Publication date: August 26, 2021
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Andrey ZHARKIKH, Kirsten TIMMS, Michael PERRY, Alexander GUTIN
  • Genes and gene signatures for diagnosis and treatment of melanoma
    Patent number: 11021752
    Abstract: Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 1, 2021
    Assignee: Myriad Genetics, Inc.
    Inventors: Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
  • Gene signatures for cancer prognosis
    Patent number: 10954568
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: March 23, 2021
    Assignee: Myriad Genetics, Inc.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia E. Reid
  • GENE SIGNATURES FOR CANCER PROGNOSIS
    Publication number: 20210071269
    Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 11, 2021
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • Gene signatures for cancer prognosis
    Patent number: 10876164
    Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 29, 2020
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
    Publication number: 20200399713
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • Method for treating cancer
    Patent number: 10851425
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: December 1, 2020
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES FOR PREDICTING CHEMOTHERAPY BENEFIT
    Publication number: 20200283855
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 10, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Alexander GUTIN, Julia REID, Ralf KRONENWETT, Marsel SCHEER
  • GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMA
    Publication number: 20200255908
    Abstract: Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
    Type: Application
    Filed: February 10, 2020
    Publication date: August 13, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Michael Bryan WARF, Benjamin ROA, Alexander GUTIN, Darl FLAKE
  • ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR INFLAMMATORY DISEASE ASSESSMENT
    Publication number: 20200249243
    Abstract: Provided herein are methods for assessing response to inflammatory disease therapy. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers to assess disease activity in inflammatory diseases, e.g., rheumatoid arthritis. Also provided are methods of adjusting disease activity scores to account for variables that can influence such scores.
    Type: Application
    Filed: July 30, 2018
    Publication date: August 6, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Ching Chang HWANG, David CHERNOFF, Alexander GUTIN, Darl FLAKE, Jerry LANCHBURY, Paul Scott EASTMAN, Eric SASSO
  • METHODS AND MATERIALS FOR ASSESSING ALLELIC IMBALANCE
    Publication number: 20200239943
    Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 30, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
    Publication number: 20200190602
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Application
    Filed: February 24, 2020
    Publication date: June 18, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • Methods and materials for assessing allelic imbalance
    Patent number: 10626449
    Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: April 21, 2020
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • Methods and materials for assessing loss of heterozygosity
    Patent number: 10612098
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: April 7, 2020
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • Genes and gene signatures for diagnosis and treatment of melanoma
    Patent number: 10612099
    Abstract: Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: April 7, 2020
    Assignee: Myriad Genetics, Inc
    Inventors: Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
  • METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
    Publication number: 20200087737
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 19, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • CANCER BIOMARKERS
    Publication number: 20200056246
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 20, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Steven STONE, Alexander GUTIN, Susanne WAGNER, Julia REID
  • METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
    Publication number: 20200010913
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 9, 2020
    Applicant: MYRIAD GENETICS, INC.
    Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • Cancer Biomarkers
    Patent number: 10519513
    Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: December 31, 2019
    Assignee: Myriad Genetics, Inc.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid